A phase 2a, randomized, double-blind, placebo-controlled, dose-escalation study to assess the safety and pharmacodynamics of ISIS 301012 [mipomersen sodium] in hypercholesterolemic subjects on stable statin therapy.

Trial Profile

A phase 2a, randomized, double-blind, placebo-controlled, dose-escalation study to assess the safety and pharmacodynamics of ISIS 301012 [mipomersen sodium] in hypercholesterolemic subjects on stable statin therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Mipomersen (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Apr 2010 Results published in the Journal of the American College of Cardiology.
    • 19 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top